



These additions apply to Exchange formularies and are effective 4/12/24

**Additions:**

**Opvee (nalmefene)** – Pharmacy benefit, Non-Preferred brand

**Balfaxar (prothrombin complex concentrate, human-lans)**– Medical benefit, no PA

**Rykindo (risperidone)** – Pharmacy benefit, Non-Preferred brand

**Risperdal Consta (risperidone microspheres)**– Pharmacy benefit, Non-Preferred brand

**Lodoco (colchicine)**– Pharmacy benefit, Non-Preferred brand, PA and QL of 1 per day

**Jesduvroq (daprodustat)**– Medical benefit, no PA (included in dialysis contract rate)

**Pokonza (potassium chloride)** – Pharmacy benefit, Non-formulary

**Motpoly XR (lacosamide)** – Pharmacy benefit, Non-formulary

**Entyvio (vedolizumab) SC** – Pharmacy benefit, Non-Preferred brand, PA

**Xacduro (sulbactam & durlobactam)** – Medical benefit, no PA

**Airsupra (albuterol and budesonide)** – Pharmacy benefit, Non-Preferred brand, PA

**Sohonos (palovarotene)**– Pharmacy benefit, Non-Preferred brand, PA

**Ojjaara (nomelotinig)** – Pharmacy benefit, Non-Preferred brand, PA

**Pombiliti (cipaglucosidase alfa-atga)** – Medical benefit, PA

**Opfolda (miglustat)** – Pharmacy benefit, Non-Preferred brand

**Adzynma (ADAMTS13, recombinant-krhn)** – Medical benefit, PA

**Changes:**

**Keytruda (pembrolizumab)** – Medical benefit, new indication

**Opdivo (nivolumab)** – Medical benefit, new indication